Tissue accumulation effect of exogenous peptides – the key to understanding the mechanisms of harmonization of immune homeostasis in patients with chronic bacterial prostatitis

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Mar 31, 2017
DOI: https://doi.org/10.30841/2307-5090.1(60).2017.115252
Keywords:
chronic bacterial prostatitis, inflammation, neoplasia, treatment, immune homeostasis, harmonization, efficiency,

##plugins.themes.bootstrap3.article.main##

Ю. І. Засєда
Клініка «Чоловіче здоров’я», м. Київ, Ukraine
О. Ф. Тацький
Фонд «Камелін-Україна», м. Київ, Ukraine

Abstract

In the article the etiology and pathogenesis of chronic bacterial prostatitis is observed and attention to the increased risk of neoplasia in patients with chronic inflammation of the prostate is accentuated. Also, the article reveals mechanisms of action of exogenous peptides in the process of harmonization of immune homeostasis,in which tissue accumulation effect plays a crucial role. Compared with the reference group, the integration of Camelyn-Bio in management of chronic bacterial prostatitis leads to better effectiveness of treatment, as evidenced by the clinical data.

##plugins.themes.bootstrap3.article.details##

How to Cite
Засєда, Ю. І., & Тацький, О. Ф. (2017). Tissue accumulation effect of exogenous peptides – the key to understanding the mechanisms of harmonization of immune homeostasis in patients with chronic bacterial prostatitis. Health of Man, (1(60), 51–56. https://doi.org/10.30841/2307-5090.1(60).2017.115252
Issue
No. 1(60) (2017)
Section
Sexology and andrology
Copyright (c) 2020 Ю. І. Засєда, О. Ф. Тацький

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Ю. І. Засєда, Клініка «Чоловіче здоров’я», м. Київ

Y.І. Zaseda

О. Ф. Тацький, Фонд «Камелін-Україна», м. Київ

O.F. Tatskyy

References

Горпинченко И.И., Мигов В.Г. Лечение больных хроническим калькулезным простатитом с применением пептидного биостимулятора Простатилен: первые результаты и перспективы // Здоровье мужчины. – No 2 (45) 2013. – С. 37–40.

Заседа Ю.И., Соломенный Р.И., Ганущак А.В. Опыт радикального консервативного лечения хронического калькулезно-фиброзного и фиброзно-калькулезного простатита // Український журнал «Чоловіче здоров’я, гендерна та психосоматична медицина». – 2016. – No 1 (03). – С. 34–43.

Евдокимов В.В. Фармакотерапия острого и хронического простатита // Трудный пациент. – 2010. – No 6 –7. – С. 40 –44.

Курченко А.I, Бенюк В.О, Потебня Г.П., Кобись В.Л., О.Ф. Тацький О.Ф., Неймарк С.О. Роль екзогенних пептидів у відновленні повноцінної імунної відповіді в умовах вторинного імунодефіциту // Здоровье женщины. – 2017. – No 1 (117). – С. 89–97.

Elssner A., Duncan M., Gavrilin M., Wewers M.D. A Novel P2X7 Receptor Activator, the Human Cathelicidin-Derived Peptide LL37, Induces IL-1 Beta Processing and Release. J Immunol 172 (8), 4987–4994. 2004.

Aldo E. Calogero, Rosita A. Condorelli, Giorgio Ivan Russo, Sandro La Vignera. Conservative Nonhormonal Options for the Treatment of Male Infertility: Antibiotics, Anti-Inflammatory Drugs, and Antioxidants. Biomed Res Int. 2017; 2017: 4650182.

Alexander RB. Prostatitis: clinical phenotyping of patients with pelvic pain. Nat Rev Urol. 2009;6:531–532.

Anderson RU, Sawyer T, Wise D, Morey A, Nathanson BH. Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2009;182:2753–2758.

Batruch I, Lecker I, Kagedan D, Smith CR, Mullen BJ, Grober E, Lo KC, Diamandis EP, Jarvi KA. Proteomic Analysis of Seminal Plasma from Normal Volunteers and Post-Vasectomy Patients Identifies over 2000 Proteins and Candidate Biomarkers of the Urogenital System. J Proteome Res. 2011;10:941–953.

Cai T, Tiscione D, Gallelli L, Verze P, Palmieri A, Mirone V, Bartoletti R, Malossini G. Serenoa repens associated with selenium and lycopene extract and bromelain and methylsulfonylmethane extract are able to improve the efficacy of levofloxacin in chronic bacterial prostatitis patients. Arch Ital Urol Androl. 2016 Oct 5;88(3):177–182.

Chao-Yueh Fan, Wen-Yen Huang, Kuen-Tze Lin, Chun-Shu Lin, Hsing-Lung Chao, Jen-Fu Yang, Cheng-Li Lin, Chia-Hung Kao. Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study. PLoS One. 2017; 12(1).

De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nature reviews Cancer. 2007;7(4):256–69.

Desireddi NV, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol. 2008;179:1857–1862.

Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50.

Hans C. Arora, Charis Eng, Daniel A. Shoskes. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann Transl Med. 2017 Jan; 5(2): 30.

Ibai Los-Arcos, Carles Pigrau, Dolors Rodríguez-Pardo, Nuria Fernández-Hidalgo, Antonia Andreu, Nieves Larrosa, Benito Almirante. Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. Antimicrob Agents Chemother. 2016 Mar; 60(3): 1854–1858.

Jon Rees, Mark Abrahams, Andrew Doble, Alison Cooper, the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015 Oct; 116(4): 509–525.

Korrovits P, Ausmees K, Mandar R, Punab M. Prevalence of asymptomatic inflammatory (National Institutes of Health Category IV) prostatitis in young men according to semen analysis. Urology. 2008;71:1010–1015.

Khadra A, Fletcher P, Luzzi G, Shattock R, Hay P. Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int. 2006;97:1043–1046.

Markku H. Vaarala, Aare Mehik, Pasi Ohtonen, Pekka A. Hellstrцm. Prostate cancer incidence in men with self-reported prostatitis after 15 years of follow-up. Oncol Lett. 2016 Aug; 12(2): 1149–1153.

Ming Shi, Xi Chen, Kangruo Ye, Yuanfei Yao, Yu Li. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore) 2016 Jun; 95(25).

Nickel J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology. 2003;62:614–617.

Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin. 2010 Jun;26(6):1433-41.

Papeљ D, Pasini M, Jeronиiж A. Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016;48:13-18. Int Urol Nephrol. 2017 Mar;49(3):457-458.

Penna G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: nterleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51:524–533.

Pilch B, Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 2006;7:R40.

Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002; 360:1144–1149.

Rico-Mata R, De Leon-Rodriguez LM, Avila EE. Effect of antimicrobial peptides derived from human cathelicidin LL-37 on Entamoeba histolytica trophozoites. Exp Parasitol. 2013; 133:300–306.

Rudick CN, Schaeffer AJ, Thumbikat P. Experimental autoimmune prostatitis induces chronic pelvic pain. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1268–R1275.

S.Ahmed, N.H.Othman. Honey as a Potential Natural Anticancer Agent: A Review of Its Mechanisms. Evid Based Complement Alternat Med. 2013; 2013:829070.

Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology. 2007;122:54–64.

S. F. Murphy, A. J. Schaeffer, P.Thumbikat. Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol. 2014 May; 11(5):259–269.

Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep. 2008; 9(3): 243–9.

Sutcliffe S, Neace C, Magnuson NS, Reeves R, Alderete JF. Trichomonosis, a common curable STI, and prostate carcinogenesis—a proposed molecular mechanism. PLoS pathogens. 2012;8(8):e1002801.

T.Hayashi, N.Takamatsu, T.Nakashima, T.Arita. Immunological Characterization of Honey Proteins and Identification of MRJP 1 as an IgE-binding protein. Biosci Biotechnol Biochem. 2011;75(3):556-60.

Tripp DA, Curtis Nickel J, Landis JR, Wang YL, Knauss JS. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int. 2004;94:1279–1282.

Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68:2611–2632.

Vicari LO, Castiglione R, Salemi M, Vicari BO, Mazzarino MC, Vicari E. Effect of levofloxacin treatment on semen hyperviscosity in chronic bacterial prostatitis patients. Andrologia. 2016 May;48(4):380-8.

Wagenlehner FM, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56:544–551.

Wang J, Yan D, Liang K, Xu Z. A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016 Jan;48(1):13–8.

Waldemar Biaіek, Sіawomir Rudzki, Paweі Iberszer, Lech Wronecki. Granulomatous prostatitis after intravesical immunotherapy mimicking prostate cancer. J Ultrason. 2016 Dec; 16(67):404–410.

Walz J, et al. Impact of chronic prostatitislike symptoms on the quality of life in a large group of men. BJU Int. 2007;100:1307–1311.

Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, Wu K, Yu J, Sung JJ, Cho CH. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer. 2010; 127: 1741–1747.

Yang Yang, Shuai Hu, Jie Liu, Yun Cui, Yu Fan, Tianjing Lv, Libo Liu, Jun Li, Qun He, Wenke Han, Wei Yu, Yin Sun, Jie Jin. CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway. Sci Rep. 2017; 7: 42893.

Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005;7:179–196.